Criteria to define difficult‐to‐treat (DTT) inflammatory bowel disease (IBD) have recently been proposed, yet the inclusion and participation of patients with DTT‐IBD in randomized controlled trials (RCTs) are heterogeneous and poorly defined.
T. Parigi, V. Solitano, H. Mekonnen et al.· Alimentary Pharmacology and...· 0 citations
BACKGROUND & AIMS
Advanced therapies (ATs) are central to the management of moderate-to-severe ulcerative colitis (UC). The expanding therapeutic landscape and limited head-to-head trials necessitate updated comparative effectiveness analyses. We performed a systematic review and network meta-analysis (NMA) to assess t...
Pablo A. Olivera, Juan S. Lasa, Siddharth Singh et al.· Clinical Gastroenterology an...· 0 citations
BACKGROUND AND AIMS
The role of therapeutic drug monitoring (TDM) in optimizing vedolizumab (VDZ) therapy for Crohn's disease (CD) and ulcerative colitis (UC) remains unclear. Prior evidence was limited by small sample size and heterogeneous endpoints. We synthesized the available evidence on the association of VDZ tro...
Mostafa A. Soliman, Alessandra Saraga, A. Gade et al.· Clinical Gastroenterology an...· 1 citation
Simple Summary Immune checkpoint inhibitors help the body’s immune system attack tumors and have greatly improved survival for many cancer patients. However, by boosting the immune system, these drugs can also cause it to attack healthy tissue, and inflammation of the bowel is one of the most common and serious side ef...
C. S. Matichecchia, F. Fanizzi, A. Zilli et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.